What is Micreos?
Micreos is at the forefront of dermatological innovation, focusing on the discovery and development of engineered endolysin technology. This advanced approach targets and eliminates harmful pathogens such as Staphylococcus aureus, a common exacerbating factor in skin conditions, while crucially preserving the beneficial skin microbiome. The company's commitment is directed towards addressing substantial unmet medical needs within the dermatology sector, positioning itself as a key player in the biotech landscape.
How much funding has Micreos raised?
Micreos has raised a total of $108.6M across 4 funding rounds:
Private Equity
$13.4M
Unspecified
$33.8M
Unspecified
$37.1M
Other Financing Round
$24.4M
Private Equity (2016): $13.4M, investors not publicly disclosed
Unspecified (2019): $33.8M led by Undisclosed
Unspecified (2021): $37.1M, investors not publicly disclosed
Other Financing Round (2022): $24.4M, investors not publicly disclosed
What's next for Micreos?
With the recent infusion of capital, Micreos is poised to advance its lead molecule, MEndoB, towards clinical trials, with a projected timeline for late 2026. This strategic financing is expected to fuel further research and development, potentially revolutionizing treatments for chronic skin ailments. The company is actively seeking strategic partnerships with entities that align with its vision for transforming dermatological care, aiming to leverage its unique technology for broader market impact and patient benefit.
See full Micreos company page
